MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$133,213K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from convertible debt
Proceeds from sale of marketable...
Accrued expenses
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net income (loss)
Payments on borrowings and amend...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-62,840
5,397
-36,592
-55,792
Stock-based compensation
10,460
9,033
7,988
8,021
Depreciation and amortization
536
536
539
534
Non-cash lease expense
-54
-66
-6
-54
Non-cash interest on revenue interest financing agreement
-5,097
-5,079
-5,017
-4,855
Amortization of debt issuance costs
350
321
327
317
Change in fair value of warrant liability
0
-2,865
1,127
-612
Amortization of premium and discounts on marketable securities
711
839
1,188
1,287
Realized loss (gain) on marketable securities
9
8
3
0
Net loss on disposal of fixed assets
31
-
-
-30
Net loss on disposal of property and equipment
-
-
1
-
Loss on debt extinguishment
-9,472
-
-
-
Unrealized foreign currency transaction (loss) gain
208
21
670
210
Acquired in-process research and development
-
-
0
0
Accounts receivable
5,103
6,647
7,753
5,630
Prepaid expenses and other current assets
-2,111
4,436
2,610
669
Inventory
4,057
4,433
5,701
5,158
Interest receivable on marketable securities
627
-24
-2,242
1,543
Intangible assets
0
-
-
-
Other non-current assets
0
-3,783
145
846
Accounts payable
-9,846
12,956
-5,881
-7,059
Contract liabilities
1,311
426
-969
4,333
Accrued expenses
13,772
-12,319
12,604
8,581
Net cash used in operating activities
-42,969
5,069
-29,733
-52,889
Cash acquired from anheart acquisition
-
-
0
0
Transaction costs related to anheart acquisition
-
-
0
0
Purchases of marketable securities
67,694
82,146
44,901
167,137
Proceeds from sale of marketable securities
73,939
38,558
132,073
78,528
Cash paid for capitalized market approval intangibles
-
-
0
8,000
Purchases of property and equipment
254
48
89
12
Net cash (used in) provided by investing activities
5,991
-43,636
87,083
-96,621
Proceeds from borrowings, net of debt issuance costs and debt discounts
0
-
11,201
0
Proceeds from revenue interest financing agreement
0
-
-
-
Proceeds from convertible debt
243,750
-
-
-
Payments on revenue interest financing agreement
-
864
0
0
Payments on capped call transactions
17,135
-
-
-
Payments on borrowings and amendment fee under financing agreement
58,687
0
11,199
0
Payments on debt issuance costs
1,129
-
0
-11
Payments on finance agreement
-
-
425
68
Payments on revenue interest financing agreement
1,882
-
-
-
Proceeds from issuance of common stock under espp
-1,247
-
-777
0
Proceeds from exercises of options
3,501
908
7,709
558
Net cash provided by financing activities
170,529
44
8,063
501
Effect of foreign exchange rate changes on cash and cash equivalents
-338
-172
-224
-64
Net (decrease) increase in cash and cash equivalents
133,213
-38,695
65,189
-149,073
Cash and cash equivalents, beginning of the period
125,391
164,086
47,977
47,977
Cash and cash equivalents, end of the period
258,604
125,391
164,086
98,897
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
convertible debt
$243,750K
Proceeds from sale of
marketable securities
$73,939K
(-45.92%↓ Y/Y)
Proceeds from exercises
of options
$3,501K
(359.45%↑ Y/Y)
Proceeds from issuance of
common stock under espp
-$1,247K
(-133.96%↓ Y/Y)
Net cash provided by
financing activities
$170,529K
(-11.84%↓ Y/Y)
Net cash (used in)
provided by investing...
$5,991K
(-89.08%↓ Y/Y)
Canceled cashflow
$78,833K
Canceled cashflow
$67,948K
Net (decrease)
increase in cash and cash...
$133,213K
(-33.39%↓ Y/Y)
Canceled cashflow
$43,307K
Payments on borrowings
and amendment fee...
$58,687K
(35253.61%↑ Y/Y)
Payments on capped call
transactions
$17,135K
Payments on revenue
interest financing...
$1,882K
Payments on debt issuance
costs
$1,129K
(-82.91%↓ Y/Y)
Accrued expenses
$13,772K
(12892.45%↑ Y/Y)
Stock-based compensation
$10,460K
(-13.06%↓ Y/Y)
Loss on debt
extinguishment
-$9,472K
Non-cash interest on
revenue interest...
-$5,097K
(-1816.17%↓ Y/Y)
Prepaid expenses and
other current assets
-$2,111K
(-1236.08%↓ Y/Y)
Depreciation and
amortization
$536K
(50.56%↑ Y/Y)
Amortization of debt issuance
costs
$350K
(1844.44%↑ Y/Y)
Purchases of marketable
securities
$67,694K
(-17.11%↓ Y/Y)
Purchases of property and
equipment
$254K
(40.33%↑ Y/Y)
Net cash used in
operating activities
-$42,969K
(10.81%↑ Y/Y)
Effect of foreign
exchange rate changes on...
-$338K
(-164.06%↓ Y/Y)
Canceled cashflow
$41,798K
Net income (loss)
-$62,840K
(-6.50%↓ Y/Y)
Accounts payable
-$9,846K
(-182.86%↓ Y/Y)
Accounts receivable
$5,103K
(123.42%↑ Y/Y)
Inventory
$4,057K
(654.09%↑ Y/Y)
Contract liabilities
$1,311K
(-40.38%↓ Y/Y)
Amortization of premium and
discounts on marketable...
$711K
(-46.74%↓ Y/Y)
Interest receivable on
marketable securities
$627K
(158.65%↑ Y/Y)
Unrealized foreign
currency transaction...
$208K
(-54.08%↓ Y/Y)
Non-cash lease expense
-$54K
(-131.58%↓ Y/Y)
Net loss on disposal
of fixed assets
$31K
(191.18%↑ Y/Y)
Buy us a coffee
cropped-static1-svg
Nuvation Bio Inc. (NUVB)
cropped-static1-svg
Nuvation Bio Inc. (NUVB)